These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 80134)

  • 21. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies.
    Bini A; Fenoglio JJ; Mesa-Tejada R; Kudryk B; Kaplan KL
    Arteriosclerosis; 1989; 9(1):109-21. PubMed ID: 2643421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological behavior of higher molecular weight products of fibrinolysis.
    Chang ML; Bang NU
    J Lab Clin Med; 1977 Jul; 90(1):216-26. PubMed ID: 874368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.
    Francis CW; Connaghan DG; Marder VJ
    Circulation; 1986 Nov; 74(5):1027-36. PubMed ID: 3533310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrin/fibrinogen degradation products (FDP) in urine and serum after prolonged heavy exercise.
    Arnesen H; Akesson I; Strömme SB; Refsum HE
    Scand J Haematol; 1976 Apr; 16(4):279-84. PubMed ID: 935811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Further studies of the interaction between ristocetin and fibrinogen.
    Goh AT; Firkin BG
    Haemostasis; 1976; 5(2):57-65. PubMed ID: 950175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High fibrin/fibrinogen degradation product to fibrinogen ratio is associated with 28-day mortality and massive transfusion in severe trauma.
    Lee DH; Lee BK; Noh SM; Cho YS
    Eur J Trauma Emerg Surg; 2018 Apr; 44(2):291-298. PubMed ID: 28921171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
    Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
    Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
    Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
    Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of hemagglutination inhibition, staphylococcal clumping, and latex agglutination tests for canine fibrinolytic degradation products.
    Chen JP; Williams TK; Legendre AM
    Am J Vet Res; 1981 Dec; 42(12):2049-52. PubMed ID: 7340573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteolytic degradation products from fibrinogen and fibrin with special respect to non-covalently associated complexes. Influence of fibrin crosslinking. Lysability and other properties.
    Feddersen C
    Scand J Clin Lab Invest Suppl; 1983; 166():1-60. PubMed ID: 6226084
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of D dimer in patients with elevated fibrinogen degradation products in serum: further study in chronic myelogenous leukemia.
    Saito M; Asakura H; Jokaji H; Uotanzi C; Kumabashiri I; Yoshida T; Hashizume K; Matsuda T
    Acta Haematol; 1990; 84(3):149-55. PubMed ID: 2123066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinogen and fibrinogen/fibrin degradation products in the urine of rabbits infected with Trypanosoma (trypanozoon) brucei.
    Boreham PF; Facer CA
    Z Parasitenkd; 1977 Jul; 52(3):257-65. PubMed ID: 906631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative assessment of soluble fibrin in plasma by affinity chromatography--a comparative study with desAA-fibrin, desAABB-fibrin and fibrinogen.
    Thiel W; Delvos U; Müller-Berghaus G
    Thromb Haemost; 1985 Aug; 54(2):533-8. PubMed ID: 4082091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A method for measurement of fibrin monomer with the use of an immune precipitate of fibrinogen.
    Kisker CT; Plummer G; Taylor B; Rush R
    J Lab Clin Med; 1977 Mar; 89(3):653-8. PubMed ID: 839123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
    Lane DA; Preston FE; VanRoss ME; Kakkar VV
    Br J Haematol; 1978 Dec; 40(4):609-15. PubMed ID: 365218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
    Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M
    Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fibrin and fibrinogen degradation products in head- and neck-tumors (author's transl)].
    Wilmes EH; Hochstrasser K
    Laryngol Rhinol Otol (Stuttg); 1978 Dec; 57(12):1083-6. PubMed ID: 732487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between fibrinogen degradation products and cryofibrinogen.
    Komp DM; Donaldson MH
    Am J Pediatr Hematol Oncol; 1979; 1(2):99-102. PubMed ID: 543513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of fibrinogen-fibrin degradation products by counterelectrophoresis.
    Brody JI
    J Clin Pathol; 1972 Sep; 25(9):754-6. PubMed ID: 5086217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma.
    Koppert PW; Kuipers W; Hoegee-de Nobel B; Brommer EJ; Koopman J; Nieuwenhuizen W
    Thromb Haemost; 1987 Feb; 57(1):25-8. PubMed ID: 2438796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.